NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/27/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization121.92 mln
Float19.12 mln
Earnings Date09/16/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
3.29
Transformational upside
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
0.13
Very low leverage
ROE
-56.01
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
enGene Therapeutics is a Canadian biotechnology company focused on developing gene-based treatments for bladder cancer. Its leading drug candidate, detalimogene voraplasmid, is being developed as a standalone treatment for a form of bladder cancer that has not spread into the muscle wall. The company also has a second treatment called LEGEND currently in Phase 2 clinical testing. enGene Therapeutics is headquartered in Montreal, Canada.
